Bart A. van de Wiel

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · The Lancet Oncology · 2019 · 522 citations

Pharmacy, Oncology, Pharmacokinetics +16

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Alexander M. Menzies, Rodabe N. Amaria, Elisa A. Rozeman et al. · Nature Medicine · 2021 · 430 citations

Medicine, Clinical Sciences, Oncology +15

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · Nature Medicine · 2022 · 357 citations · Full text

Medicine, Oncology, Surgery +17

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers et al. · Nature Medicine · 2021 · 337 citations · Full text

Medicine, Clinical Sciences, Oncology +16

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

M.T. Tetzlaff, Jane L. Messina, Julie E. Stein et al. · Annals of Oncology · 2018 · 270 citations · Full text

Medicine, Oncology, Pathology +17